Browse published site content mentioning or authored by this company. Sorted by original publication date; undated items appear last.
← Back to company profileShowing 1–12 / 24 related items
This article explores how Microcrystal Electron Diffraction (MicroED) is set to revolutionize drug polymorph research workflows. Drawing upon recent news, official websites, and LinkedIn updates from Crystal Pharmatech and Eldico, it clearly distinguishes between verified facts, industry viewpoints, and information pending verification.
Crystal Pharmatech’s November 4 announcement confirms ED-1 service in Suzhou. Its service page describes integration with solid-form screening for small crystals and pharmaceutical solid forms.
Learn how to design a drug-excipient compatibility study for oral solid dosage forms using binary or multi-component mixtures and accelerated conditions.
Learn how to design forced degradation studies for candidate selection, including stress conditions, 5–20% targets, controls, and stability-indicating methods.
A section-by-section guide to the preformulation report: the data that de-risks a program, and how much depth each section needs at each stage. Real Question in Stable Form ScreeningUnderlying the com...
How high-throughput and adaptive manual screening compare when the objective is to identify and confirm the thermodynamically stable form of an API. Real Question in Stable Form ScreeningUnderlying th...
A practical framework for deciding between salt screening, cocrystal screening, or both when developing a weakly basic API.
Amorphous solid dispersions (ASDs) have become one of the most widely adopted enabling oral formulation strategies for poorly soluble drug candidates. By converting crystalline APIs into high-energy amorphous systems, ASDs significantly improve dissolution and oral bioavailability.
What a polymorph screen should cover at each development stage, what outputs to expect, and how to know if yours is thorough enough.
Solubility is not a fixed property of a drug. It depends on its physical form. This article examines how polymorphism, salt disproportionation, and amorphous recrystallization reduce solubility during development, manufacturing, and storage, and what each risk requires from the development team.
Poor aqueous solubility is one of the leading causes of failure in oral drug development. Approximately 40% of marketed drugs and up to 70–90% of drug candidates in development exhibit poor aqueous solubility, placing many compounds in Biopharmaceutics Classification System (BCS) Class II or IV categories where dissolution rate or solubility limits oral bioavailability.
What the dissolution curve does not show: the mechanisms that determine whether a supersaturating formulation actually delivers oral exposure for poorly soluble drugs. What Supersaturation Ratio Alone...
Name matches are discovery leads; verify entity identity and transaction roles in the original source. Same-field reading is kept separate.